Stay updated on Safety & Efficacy of Filgotinib & Lanraplenib in LMN Clinical Trial

Sign up to get notified when there's something new on the Safety & Efficacy of Filgotinib & Lanraplenib in LMN Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Safety & Efficacy of Filgotinib & Lanraplenib in LMN Clinical Trial page

  1. Check
    6 days ago
    No Change Detected
  2. Check
    13 days ago
    Change Detected
    Summary
    Revision: v3.4.2 appears on the page; no changes to study details, eligibility criteria, or outcome measures are observed. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2026-02-11T14:16:53.000Z thumbnail image
  3. Check
    20 days ago
    Change Detected
    Summary
    Banner notice about a lapse in government funding and NIH operating status was added, and the site revision was updated from v3.4.0 to v3.4.1; To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2026-02-04T10:24:53.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    The updates add a glossary toggle and update page metadata, including a new 'Last Update Submitted that Met QC Criteria' field and 'Revision: v3.4.0', while removing the older 'Last Update Submitted that met QC Criteria', the 'No FEAR Act data' label, and 'Revision: v3.3.4'. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2026-01-28T05:48:09.000Z thumbnail image
  5. Check
    42 days ago
    Change Detected
    Summary
    Revision updated from v3.3.3 to v3.3.4 on the page. This appears to be a maintenance update and does not modify study information or essential content.
    Difference
    0.1%
    Check dated 2026-01-14T03:17:45.000Z thumbnail image
  6. Check
    63 days ago
    Change Detected
    Summary
    A new Locations section was added listing study sites across Alabama, California, Florida, Georgia, Michigan, and North Carolina. The previous per-state location headings were removed, and the HHS Vulnerability Disclosure link was removed.
    Difference
    0.7%
    Check dated 2025-12-23T20:56:51.000Z thumbnail image
  7. Check
    91 days ago
    Change Detected
    Summary
    The Publications section text was updated to clarify that publications are automatically filled from PubMed, with the revision version updated from v3.2.0 to v3.3.2.
    Difference
    0.1%
    Check dated 2025-11-25T10:32:22.000Z thumbnail image

Stay in the know with updates to Safety & Efficacy of Filgotinib & Lanraplenib in LMN Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Safety & Efficacy of Filgotinib & Lanraplenib in LMN Clinical Trial page.